Evidence map›Paper›PMID 30267203›Full record

ArticleStem cell reviews and reports2018

Endothelial Colony-Forming Cells Do Not Participate to Fibrogenesis in a Bleomycin-Induced Pulmonary Fibrosis Model in Nude Mice.

Adeline Blandinières, Thomas Gille, Jérémy Sadoine, Ivan Bièche, Lofti Slimani, Blandine Dizier, Pascale Gaussem, Catherine Chaussain, Carole Planes, Peter Dorfmüller and 2 more

Abstract read
PubMed Publisher
In one paragraph

Article in Stem cell reviews and reports, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed, 1 pooled it
1.3field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 1 synthesis or guideline pooled it, 16 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. The vascular perspective on acute and chronic lung disease.The Journal of clinical investigation · 2023
    Review
  5. Article
  6. Pathological Roles for Endothelial Colony-Forming Cells in Neonatal and Adult Lung Disease.American journal of respiratory cell and molecular biology · 2023
    Review
  7. Evidence-based complementary and alternative medicine : eCAM · 2022
    Article
  8. Article
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 5 institutions in 1 country.

Adeline BlandinièresAP-HP, European Georges Pompidou Hospital, Hematology Department , Paris, France.
Thomas GilleAP-HP, Avicenne Hospital, Physiology Department , Paris, France.
Jérémy SadoineLaboratory EA 2496 Orofacial Pathologies, Imaging and Biotherapies, Montrouge, France.
Ivan BiècheParis Descartes University, Sorbonne Paris Cité, Paris, France.
Lofti SlimaniLaboratory EA 2496 Orofacial Pathologies, Imaging and Biotherapies, Montrouge, France.
Blandine DizierParis Descartes University, Sorbonne Paris Cité, Paris, France.
Pascale GaussemAP-HP, European Georges Pompidou Hospital, Hematology Department , Paris, France.
Catherine ChaussainLaboratory EA 2496 Orofacial Pathologies, Imaging and Biotherapies, Montrouge, France.
Carole PlanesAP-HP, Avicenne Hospital, Physiology Department , Paris, France.
Peter DorfmüllerCentre Chirurgical Marie Lannelongue, INSERM U999, Le Plessis Robinson, France.
Dominique Israël-BietParis Descartes University, Sorbonne Paris Cité, Paris, France.
David M SmadjaAP-HP, European Georges Pompidou Hospital, Hematology Department , Paris, France. david.smadja@parisdescartes.fr.
Assistance Publique – Hôpitaux de Paris · FRLaboratory Orofacial Pathologies, Imaging and Biotherapies · FRInserm · FRUniversité Paris Cité · FRHôpital Européen Georges-Pompidou · FR

Funding

Chancellerie des Universités de Paris (FR) Chancellerie des Universités de Paris (FR)PRES PRESPROMEX STIFTUNG FUR DIE FORSCHUNG foundation PROMEX STIFTUNG FUR DIE FORSCHUNG foundation
6 · The paper itself

Abstract

Idiopathic pulmonary fibrosis (IPF) is a devastating lung disease characterized by fibroblast proliferation, extracellular matrix deposition, destruction of pulmonary alveolar architecture and vascular remodeling. Apart pirfenidone or nintendanib that only slow down the fibrotic process, there is no curative treatment other than lung transplantation. Because cell therapy approaches have been proposed in IPF, we hypothesized that injection of endothelial colony-forming cells (ECFCs), the vasculogenic subtype of endothelial progenitor cells, could modulate fibrosis in a Nude mouse model of bleomycin induced-pulmonary fibrosis. Mice were injected with ECFCs isolated from cord blood and from peripheral blood of adult IPF patients at two time-points: during the development of the fibrosis or once the fibrosis was constituted. We assessed morbidity, weight variation, collagen deposition, lung imaging by microCT, Fulton score and microvascular density. Neither ECFCs isolated from cord blood nor from IPF patients were able to modulate fibrosis or vascular density during fibrogenesis or when fibrosis was constituted. These findings indicate that human ECFCs do not promote an adaptive regenerative response in the lung upon fibrosis or angiogenic process in the setting of bleomycin-induced pulmonary fibrosis in Nude mice.

Indexed as

LungPulmonary FibrosisX-Ray MicrotomographyAnimalsBleomycinDisease Models, AnimalEndothelial Progenitor CellsHumansMiceMice, NudeBleomycinBleomycinECFCEndothelial colony forming cellsEndothelial progenitor cellsFibrosisLung

Identifiers

PMID30267203
OpenAlexW2893048975

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.